Spots Global Cancer Trial Database for refractory acute myeloid leukemia
Every month we try and update this database with for refractory acute myeloid leukemia cancer trials from around the world to help patients and their families find trials that might be right for them.
We offer this 100% free of charge and do not endorse any of the trials listed here, we hope it helps you or a loved one.
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
| Study title | NCT ID | Conditions | Interventions | Eligibility | Organization | Link |
|---|---|---|---|---|---|---|
| A Study of ASP2215 Versus Salvage Chemotherapy in Patients With Relapsed or Refractory Acute Myeloid Leukemia (AML) With FMS-like Tyrosine Kinase (FLT3) Mutation | NCT02421939 | Leukemia, Acute... | gilteritinib LoDAC (Low Dose... Azacitidine MEC (Mitoxantro... FLAG-IDA (Granu... | 18 Years - | Astellas Pharma Inc | |
| Entrectinib in Combination With ASTX727 for the Treatment of Relapsed/Refractory TP53 Mutated Acute Myeloid Leukemia | NCT05396859 | Acute Myeloid L... Recurrent Acute... Refractory Acut... | Decitabine and ... Entrectinib Laboratory Biom... | 18 Years - | OHSU Knight Cancer Institute | |
| A Study of CD371-YSNVZIL-18 CAR T Cells in People With Acute Myeloid Leukemia | NCT06017258 | Refractory Acut... Relapsed Acute ... Acute Myeloid L... Acute Myeloid L... Acute Myeloid L... | CD371-YSNVZ-IL1... | 1 Year - | Memorial Sloan Kettering Cancer Center | |
| Cytokine-induced Memory-like NK Cells in Relapsed/Refractory AML and MDS | NCT04893915 | Relapsed Acute ... Refractory Acut... Myelodysplastic... | Cytokine-induce... Fludarabine Cyclophosphamid... Donor Leukapher... Interleukin-2 | 18 Years - | Washington University School of Medicine | |
| Decitabine With GCLAM for Adults With Newly Diagnosed, Relapsed, or Refractory AML or High-Risk MDS | NCT02921061 | Mixed Phenotype... Previously Trea... Recurrent Adult... Recurrent High ... Refractory Acut... Refractory High... Untreated Adult... | Cladribine Cytarabine Decitabine Filgrastim Laboratory Biom... Mitoxantrone Hy... | 18 Years - | Fred Hutchinson Cancer Center | |
| Pevonedistat and Decitabine in Treating Patients With High Risk Acute Myeloid Leukemia | NCT03009240 | Acute Myeloid L... Recurrent Acute... Refractory Acut... Secondary Acute... Therapy-Related... Untreated Adult... | Decitabine Laboratory Biom... Pevonedistat Pharmacological... | 18 Years - | City of Hope Medical Center | |
| Efficacy and Safety of HVA Regimens as Salvage Treatment in rrAML | NCT04424147 | Refractory Acut... Relapsed Acute ... Salvage Treatme... HVA Regimen | HVA Regimens as... | 18 Years - 65 Years | Nanfang Hospital, Southern Medical University | |
| Study of Selinexor and Venetoclax in Combination With Chemotherapy in Pediatric and Young Adult Patients With Refractory or Relapsed Acute Myeloid Leukemia | NCT04898894 | Acute Leukemia ... Acute Myeloid L... Refractory Acut... Refractory Acut... | Venetoclax Selinexor Cytarabine Fludarabine Filgrastim Methotrexate methotrexate/hy... | 2 Years - 30 Years | St. Jude Children's Research Hospital | |
| Pembrolizumab and Decitabine With or Without Venetoclax in Treating Patients With Acute Myeloid Leukemia or Myelodysplastic Syndrome That Is Newly-Diagnosed, Recurrent, or Refractory | NCT03969446 | Acute Myeloid L... Myelodysplastic... Recurrent Acute... Recurrent Myelo... Refractory Acut... Refractory Myel... | Decitabine Pembrolizumab Venetoclax | 18 Years - | City of Hope Medical Center | |
| Liposome-encapsulated Daunorubicin-Cytarabine and Venetoclax in Treating Participants With Relapsed, Refractory or Untreated Acute Myeloid Leukemia | NCT03629171 | Recurrent Acute... Refractory Acut... | Liposome-encaps... Venetoclax | 18 Years - | M.D. Anderson Cancer Center | |
| Aza-Ven Followed by Reduced Toxicity Conditioning Regimen (MBF) as Salvage Therapy for Refractory AML. | NCT04904237 | Refractory Acut... | Aza-Ven-allo-HS... | 16 Years - 65 Years | Shanghai Jiao Tong University School of Medicine | |
| Combination of Venetoclax, Hypomethylation Agent and Low-dose Cytarabine as a Salvage Therapy for Acute Myeloid Leukemia | NCT05362942 | Relapsed Acute ... Refractory Acut... Minimal Residua... | Venetoclax, Dec... | 18 Years - | Beijing 302 Hospital | |
| Phase I Trial of AZD1775 and Belinostat in Treating Patients With Relapsed or Refractory Myeloid Malignancies or Untreated Acute Myeloid Leukemia | NCT02381548 | Acute Myeloid L... Blast Phase Chr... Myelodysplastic... Previously Trea... Recurrent Adult... Recurrent Chron... Refractory Acut... Refractory Chro... Secondary Acute... Therapy-Related... Untreated Adult... | Adavosertib Belinostat Laboratory Biom... Pharmacological... | 18 Years - | National Cancer Institute (NCI) | |
| Vyxeos for Re-induction Treatment of Acute Myeloid Leukemia Patients With Persistent Disease After Induction | NCT04049539 | Blasts More Tha... Persistent Dise... Refractory Acut... | Liposome-encaps... | 18 Years - 75 Years | Ohio State University Comprehensive Cancer Center | |
| Pevonedistat With Azacitidine Versus Azacitidine Alone in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia | NCT03745352 | Recurrent Acute... Refractory Acut... | Azacitidine Pevonedistat | 18 Years - | National Cancer Institute (NCI) | |
| Comparing ATG or Post-Transplant Cyclophosphamide to Calcineurin Inhibitor-Methotrexate as GVHD Prophylaxis After Myeloablative Unrelated Donor Peripheral Blood Stem Cell Transplantation | NCT03602898 | Acute Lymphobla... Acute Myeloid L... Chronic Myelomo... Chronic Phase C... Hematopoietic a... Myelodysplastic... Myelofibrosis Myeloproliferat... Recurrent Acute... Recurrent Hodgk... Recurrent Non-H... Refractory Acut... Therapy-Related... | Anti-Thymocyte ... Busulfan Cyclophosphamid... Cyclosporine Fludarabine Pho... Methotrexate Peripheral Bloo... Quality-of-Life... Questionnaire A... Tacrolimus Total-Body Irra... | - 65 Years | Fred Hutchinson Cancer Center | |
| Salsalate, Venetoclax, and Decitabine or Azacitidine for the Treatment of Acute Myeloid Leukemia or Advanced Myelodysplasia/Myeloproliferative Disease | NCT04146038 | Acute Myeloid L... Chronic Myelomo... Myeloblasts 10 ... Myelodysplastic... Myeloproliferat... Recurrent Acute... Refractory Acut... Secondary Acute... | Azacitidine Decitabine Salsalate Venetoclax | 18 Years - | Rutgers, The State University of New Jersey | |
| Quizartinib With Azacitidine or Cytarabine in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia or Myelodysplastic Syndrome | NCT01892371 | FLT3 Gene Mutat... FLT3 Internal T... Recurrent Acute... Recurrent Chron... Recurrent Myelo... Refractory Acut... Refractory Chro... Refractory Myel... | Azacitidine Cytarabine Quizartinib | 18 Years - | M.D. Anderson Cancer Center | |
| Azacitidine, Venetoclax, and Trametinib for the Treatment of Relapsed or Refractory Acute Myeloid Leukemia or Higher-Risk Myelodysplastic Syndrome | NCT04487106 | Recurrent Acute... Recurrent Chron... Recurrent Myelo... Refractory Acut... Refractory Chro... Refractory Myel... | Azacitidine Trametinib Venetoclax | 18 Years - | M.D. Anderson Cancer Center | |
| Low Dose Daunorubicin in Pediatric Relapsed/Refractory Acute Leukemia | NCT04562792 | Relapsed Pediat... Relapsed Pediat... Refractory Acut... Refractory Acut... | Daunorubicin | 1 Year - 21 Years | Children's Mercy Hospital Kansas City | |
| Enasidenib for the Treatment of Relapsed or Refractory Acute Myeloid Leukemia Patients With an IDH2 Mutation | NCT04203316 | Recurrent Acute... Refractory Acut... | Biospecimen Col... Bone Marrow Asp... Bone Marrow Bio... Enasidenib Enasidenib Mesy... | 24 Months - 21 Years | Children's Oncology Group | |
| Avelumab and Azacitidine in Treating Patients With Refractory or Relapsed Acute Myeloid Leukemia | NCT02953561 | Acute Myeloid L... Recurrent Acute... Refractory Acut... | Avelumab Azacitidine Laboratory Biom... | 18 Years - | M.D. Anderson Cancer Center | |
| ASTX727, Venetoclax, and Gilteritinib for the Treatment of Newly Diagnosed, Relapsed or Refractory FLT3-Mutated Acute Myeloid Leukemia or High-Risk Myelodysplastic Syndrome | NCT05010122 | Acute Myeloid L... Myelodysplastic... Recurrent Acute... Refractory Acut... | Decitabine and ... Gilteritinib Venetoclax | 18 Years - | M.D. Anderson Cancer Center | |
| Cytokine-induced Memory-like NK Cells in Combination With Chemotherapy in Pediatric Patents With Refractory or Relapsed AML | NCT04354025 | Refractory Acut... Relapsed Acute ... | Cytokine induce... Fludarabine Ara-C G-CSF Interleukin-2 Leukapheresis | 1 Year - 21 Years | Washington University School of Medicine | |
| Safety Study of Thioridazine in Combination With Cytarabine to Treat Relapsed or Refractory Acute Myeloid Leukemia | NCT02096289 | Acute Myeloid L... | Thioridazine | 55 Years - 80 Years | Ontario Clinical Oncology Group (OCOG) | |
| Pevonedistat, Azacitidine, Fludarabine Phosphate, and Cytarabine in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia or Myelodysplastic Syndrome | NCT03813147 | Acute Myeloid L... Recurrent Acute... Recurrent Myelo... Refractory Acut... Refractory Myel... | Azacitidine Cytarabine Fludarabine Pho... Methotrexate Pevonedistat Therapeutic Hyd... | 1 Month - 21 Years | National Cancer Institute (NCI) | |
| Cladribine, Idarubicin, Cytarabine, and Quizartinib in Treating Patients With Newly Diagnosed, Relapsed, or Refractory Acute Myeloid Leukemia or High-Risk Myelodysplastic Syndrome | NCT04047641 | Acute Myeloid L... Blasts 20 Perce... High Risk Myelo... Recurrent Acute... Recurrent Acute... Recurrent High ... Refractory Acut... Refractory High... | Cladribine Cytarabine Idarubicin Quizartinib | 18 Years - | M.D. Anderson Cancer Center | |
| Eltanexor and Venetoclax in Relapsed or Refractory Myelodysplastic Syndrome and Acute Myeloid Leukemia | NCT06399640 | Relapsed Myelod... Refractory Myel... Acute Myeloid L... Recurrent Acute... Refractory Acut... | Eltanexor Venetoclax Bone Marrow Asp... Biospecimen Col... | 18 Years - | Vanderbilt-Ingram Cancer Center | |
| CPX-351 and Ivosidenib for the Treatment of IDH1 Mutated Acute Myeloid Leukemia or High-Risk Myelodysplastic Syndrome | NCT04493164 | Acute Myeloid L... Myelodysplastic... Myeloproliferat... Recurrent Acute... Refractory Acut... | Ivosidenib Liposome-encaps... | 18 Years - | M.D. Anderson Cancer Center | |
| Flotetuzumab for the Treatment of Pediatric Recurrent or Refractory Acute Myeloid Leukemia | NCT04158739 | Recurrent Acute... Refractory Acut... | Cytarabine Flotetuzumab | - 20 Years | Children's Oncology Group | |
| Personalized Targeted Preparative Regimen Before T-depleted Allogeneic HSCT in Children With Chemoresistent Acute Leukemias | NCT04000698 | Refractory Acut... Refractory Acut... | Preparative reg... | - 25 Years | Federal Research Institute of Pediatric Hematology, Oncology and Immunology | |
| 211At-BC8-B10 Followed by Donor Stem Cell Transplant in Treating Patients With Relapsed or Refractory High-Risk Acute Leukemia or Myelodysplastic Syndrome | NCT03670966 | Acute Lymphobla... Acute Myeloid L... Acute Myeloid L... Chronic Myelomo... Myelodysplastic... Recurrent Acute... Recurrent Acute... Refractory Acut... Refractory Acut... Recurrent Mixed... Refractory Mixe... Hematopoietic a... | Astatine At 211... Cyclophosphamid... Total-Body Irra... Peripheral Bloo... Bone Marrow Tra... Mycophenolate M... Recombinant Gra... Fludarabine Pho... Tacrolimus Bone Marrow Asp... Biospecimen Col... | 18 Years - 75 Years | Fred Hutchinson Cancer Center | |
| CPX-351 as a Novel Approach for the Treatment of Older Patients With AML and MDS | NCT04668885 | Refractory Acut... Relapsed Acute ... Myelodysplastic... | CPX-351 | 60 Years - | Case Comprehensive Cancer Center | |
| Testing the Addition of an Anti-cancer Drug, M3814, to the Usual Treatment (Mitoxantrone, Etoposide, and Cytarabine) for Relapsed or Refractory Acute Myeloid Leukemia | NCT03983824 | Recurrent Acute... Refractory Acut... | Cytarabine Etoposide Phosp... Mitoxantrone Hy... Peposertib | 18 Years - | National Cancer Institute (NCI) | |
| Ipilimumab and Decitabine in Treating Patients With Relapsed or Refractory Myelodysplastic Syndrome or Acute Myeloid Leukemia | NCT02890329 | Previously Trea... Recurrent Acute... Recurrent Acute... Recurrent Myelo... Refractory Acut... Refractory Myel... Secondary Acute... Secondary Myelo... | Decitabine Ipilimumab | 18 Years - | National Cancer Institute (NCI) | |
| VSV-hIFNbeta-NIS in Treating Patients With Relapsed or Refractory Multiple Myeloma, Acute Myeloid Leukemia or Lymphoma | NCT03017820 | B-Cell Non-Hodg... Histiocytic and... Myelodysplastic... Previously Trea... Recurrent Adult... Recurrent Anapl... Recurrent Angio... Recurrent Mycos... Recurrent Plasm... Recurrent Prima... Recurrent T-Cel... Refractory Acut... Refractory Anap... Refractory Angi... Refractory Myco... Refractory Peri... Refractory Plas... Refractory Prim... Refractory T-Ce... | Biopsy Biospecimen Col... Bone Marrow Bio... Computed Tomogr... Cyclophosphamid... Positron Emissi... Recombinant Ves... Single Photon E... Cemiplimab | 18 Years - | Mayo Clinic | |
| Daratumumab in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia or High-Risk Myelodysplastic Syndrome | NCT03067571 | High Risk Myelo... Recurrent Acute... Refractory Acut... | Daratumumab | 18 Years - | M.D. Anderson Cancer Center | |
| Sequential Conditioning in Haploidentical Transplantation for Refractory Acute Myeloid Leukemia | NCT03035422 | Refractory Acut... | Sequential Pack... Transfusion gra... Prevention of G... Care supports Lymphocyte inje... | 18 Years - 60 Years | Association for Training, Education, and Research in Hematology, Immunology, and Transplantation | |
| Navitoclax, Venetoclax, and Decitabine for the Treatment of Relapsed or Refractory Acute Myeloid Leukemia Previously Treated With Venetoclax | NCT05222984 | Recurrent Acute... Refractory Acut... | Decitabine Navitoclax Venetoclax | 16 Years - | City of Hope Medical Center | |
| A Study of Bisantrene Combined With Cytarabine or With Decitabine for Adult Subjects With Extramedullary AML and MDS | NCT05456269 | Acute Myeloid L... Recurrent Acute... Refractory Acut... Higher Risk Mye... Chronic Myelomo... | Bisantrene Dihy... Bisantrene Dihy... Cytarabine Hydr... Decitabine and ... | 18 Years - | Race Oncology Ltd | |
| Phase 0- Pilot Study of Pembrolizumab on Immune Cells in Patient With Refractory Acute Myeloid Leukemia | NCT03291353 | Refractory Acut... | pembrolizumab | 18 Years - | University of Pittsburgh | |
| JNJ-40346527 in Treating Participants With Relapsed or Refractory Acute Myeloid Leukemia | NCT03557970 | Recurrent Acute... Refractory Acut... | Edicotinib Pharmacokinetic... | 18 Years - | OHSU Knight Cancer Institute | |
| Venetoclax With Combination Chemotherapy in Treating Patients With Newly Diagnosed or Relapsed or Refractory Acute Myeloid Leukemia | NCT03214562 | High Risk Myelo... Recurrent Acute... Refractory Acut... | Cytarabine Filgrastim Fludarabine Idarubicin Pegfilgrastim Venetoclax | 18 Years - | M.D. Anderson Cancer Center | |
| Alvocidib in Combination With Decitabine and Venetoclax in Patients With Relapsed or Refractory AML or as Frontline Therapy in Unfit Patients With AML | NCT04493099 | Recurrent Acute... Refractory Acut... | Alvocidib Hydro... Decitabine Venetoclax | 18 Years - | M.D. Anderson Cancer Center | |
| A Three-part Study of Eltrombopag in Thrombocytopenic Subjects With Myelodysplastic Syndromes or Acute Myeloid Leukemia | NCT01440374 | Thrombocytopaen... | eltrombopag placebo | 18 Years - 110 Years | Novartis | |
| A Study of the Drug IMGN632 in Children With Leukemia That Has Come Back After Treatment or is Difficult to Treat | NCT05320380 | Recurrent Acute... Recurrent B Acu... Recurrent Mixed... Recurrent T Acu... Refractory Acut... Refractory B Ac... Refractory Mixe... Refractory T Ac... | Anti-CD123 ADC ... Bone Marrow Asp... Cytarabine Fludarabine Pho... Hydrocortisone ... Liposome-encaps... Methotrexate Prednisolone | 12 Months - 22 Years | Children's Oncology Group | |
| Sequential Conditioning in Haploidentical Transplantation for Refractory Acute Myeloid Leukemia | NCT03035422 | Refractory Acut... | Sequential Pack... Transfusion gra... Prevention of G... Care supports Lymphocyte inje... | 18 Years - 60 Years | Association for Training, Education, and Research in Hematology, Immunology, and Transplantation | |
| Milademetan Tosylate and Low-Dose Cytarabine With or Without Venetoclax in Treating Participants With Recurrent or Refractory Acute Myeloid Leukemia | NCT03634228 | Acute Myeloid L... Recurrent Acute... Refractory Acut... | Cytarabine Milademetan Tos... Venetoclax | 18 Years - | M.D. Anderson Cancer Center | |
| Pevonedistat and Decitabine in Treating Patients With High Risk Acute Myeloid Leukemia | NCT03009240 | Acute Myeloid L... Recurrent Acute... Refractory Acut... Secondary Acute... Therapy-Related... Untreated Adult... | Decitabine Laboratory Biom... Pevonedistat Pharmacological... | 18 Years - | City of Hope Medical Center | |
| Salsalate, Venetoclax, and Decitabine or Azacitidine for the Treatment of Acute Myeloid Leukemia or Advanced Myelodysplasia/Myeloproliferative Disease | NCT04146038 | Acute Myeloid L... Chronic Myelomo... Myeloblasts 10 ... Myelodysplastic... Myeloproliferat... Recurrent Acute... Refractory Acut... Secondary Acute... | Azacitidine Decitabine Salsalate Venetoclax | 18 Years - | Rutgers, The State University of New Jersey | |
| Selective Depletion of CD45RA+ T Cells From Allogeneic Peripheral Blood Stem Cell Grafts From HLA-Matched Related and Unrelated Donors in Preventing GVHD | NCT02220985 | Accelerated Pha... Acute Biphenoty... Acute Leukemia ... Acute Undiffere... Allogeneic Hema... Blast Phase Chr... Blastic Plasmac... Childhood Acute... Childhood Acute... Donor Lymphoblastic L... Myelodysplastic... Myelodysplastic... Myelodysplastic... Recurrent Acute... Recurrent Acute... Recurrent Child... Recurrent Child... Recurrent Chron... Refractory Acut... Refractory Acut... Acute Lymphobla... Acute Myeloid L... | Allogeneic Hema... Cyclophosphamid... Fludarabine Pho... Laboratory Biom... Methotrexate Mycophenolate M... Peripheral Bloo... Peripheral Bloo... Tacrolimus Thiotepa Total-Body Irra... | - 60 Years | Fred Hutchinson Cancer Center | |
| Ruxolitinib and Venetoclax in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia | NCT03874052 | Acute Myeloid L... Recurrent Acute... Refractory Acut... | Ruxolitinib Venetoclax | 18 Years - | OHSU Knight Cancer Institute | |
| Venetoclax With Combination Chemotherapy in Treating Patients With Newly Diagnosed or Relapsed or Refractory Acute Myeloid Leukemia | NCT03214562 | High Risk Myelo... Recurrent Acute... Refractory Acut... | Cytarabine Filgrastim Fludarabine Idarubicin Pegfilgrastim Venetoclax | 18 Years - | M.D. Anderson Cancer Center | |
| Talazoparib and Gemtuzumab Ozogamicin for the Treatment of CD33 Positive Relapsed or Refractory Acute Myeloid Leukemia | NCT04207190 | Recurrent Acute... Refractory Acut... | Gemtuzumab Ozog... Quality-of-Life... Questionnaire A... Talazoparib Talazoparib Tos... | 18 Years - | Roswell Park Cancer Institute | |
| CLAG-M or FLAG-Ida Chemotherapy and Reduced-Intensity Conditioning Donor Stem Cell Transplant for the Treatment of Relapsed or Refractory Acute Myeloid Leukemia, Myelodysplastic Syndrome, or Chronic Myelomonocytic Leukemia | NCT04375631 | Recurrent Acute... Recurrent Chron... Recurrent Myelo... Refractory Acut... Refractory Chro... Refractory Mixe... Refractory Myel... Refractory Acut... Refractory Acut... | Cladribine Cyclophosphamid... Cyclosporine Cytarabine Filgrastim Hematopoietic C... Mitoxantrone Mycophenolate M... Mycophenolate S... Total-Body Irra... Idarubicin Fludarabine Cytarabine Multigated Acqu... Echocardiograph... X-Ray Imaging Bone Marrow Bio... Bone Marrow Asp... | 18 Years - | Fred Hutchinson Cancer Center | |
| Quizartinib, Decitabine, and Venetoclax in Treating Participants With Untreated or Relapsed Acute Myeloid Leukemia or High Risk Myelodysplastic Syndrome | NCT03661307 | Acute Myeloid L... Myelodysplastic... Recurrent Acute... Recurrent Myelo... Refractory Acut... | Decitabine Quizartinib Venetoclax | 18 Years - | M.D. Anderson Cancer Center | |
| Enasidenib and Azacitidine in Treating Patients With Recurrent or Refractory Acute Myeloid Leukemia and IDH2 Gene Mutation | NCT03683433 | Acute Bilineal ... Acute Biphenoty... Chronic Myelomo... IDH2 Gene Mutat... Myelodysplastic... Recurrent Acute... Refractory Acut... | Azacitidine Enasidenib Mesy... | 18 Years - | M.D. Anderson Cancer Center | |
| Phase I Trial of Cabozantinib in Patients With Relapsed or Refractory Acute Myeloid Leukemia | NCT01961765 | Relapsed Acute ... Refractory Acut... | cabozantinib | 18 Years - | Massachusetts General Hospital | |
| STAT Inhibitor OPB-111077, Decitabine and Venetoclax in Treating Patients With Acute Myeloid Leukemia That Is Refractory, Relapsed or Newly Diagnosed and Ineligible for Intensive Chemotherapy | NCT03063944 | Acute Myeloid L... Recurrent Acute... Refractory Acut... | STAT Inhibitor ... Decitabine Venetoclax Laboratory Biom... | 18 Years - | Thomas Jefferson University | |
| Ficlatuzumab With High Dose Cytarabine in Relapsed and Refractory AML | NCT02109627 | Acute Myeloid L... Relapsed Acute ... Refractory Acut... | Ficlatuzumab Cytarabine | 18 Years - | University of California, San Francisco | |
| Enasidenib for the Treatment of Relapsed or Refractory Acute Myeloid Leukemia Patients With an IDH2 Mutation | NCT04203316 | Recurrent Acute... Refractory Acut... | Biospecimen Col... Bone Marrow Asp... Bone Marrow Bio... Enasidenib Enasidenib Mesy... | 24 Months - 21 Years | Children's Oncology Group | |
| Comprehensive Genomic Profiling and Next Generation Functional Drug Screening for Patients With Aggressive Haematological Malignancies | NCT04470947 | Advanced Lympho... Refractory Lymp... Refractory Leuk... Refractory Acut... Refractory T-Ce... | Next generation... Comprehensive g... | 18 Years - | Medical University of Vienna | |
| Decitabine, Vorinostat, and Cytarabine in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia or Myelodysplastic Syndrome | NCT01130506 | Previously Trea... Recurrent Adult... Refractory Acut... Secondary Acute... Therapy-Related... Untreated Adult... | Cytarabine Decitabine Laboratory Biom... Pharmacological... Vorinostat | 18 Years - 59 Years | National Cancer Institute (NCI) | |
| Minnelide in Adult Patients With Relapsed or Refractory Acute Myeloid Leukemia | NCT03347994 | Acute Myeloid L... | Minnelide | 18 Years - | University of Miami | |
| Safety Study of AKN-028 in Patients With Acute Myelogenous Leukemia | NCT01573247 | Acute Myeloid L... | AKN-028 | 18 Years - | Akinion Pharmaceuticals AB | |
| VSV-hIFNbeta-NIS in Treating Patients With Relapsed or Refractory Multiple Myeloma, Acute Myeloid Leukemia or Lymphoma | NCT03017820 | B-Cell Non-Hodg... Histiocytic and... Myelodysplastic... Previously Trea... Recurrent Adult... Recurrent Anapl... Recurrent Angio... Recurrent Mycos... Recurrent Plasm... Recurrent Prima... Recurrent T-Cel... Refractory Acut... Refractory Anap... Refractory Angi... Refractory Myco... Refractory Peri... Refractory Plas... Refractory Prim... Refractory T-Ce... | Biopsy Biospecimen Col... Bone Marrow Bio... Computed Tomogr... Cyclophosphamid... Positron Emissi... Recombinant Ves... Single Photon E... Cemiplimab | 18 Years - | Mayo Clinic | |
| Enasidenib and Azacitidine in Treating Patients With Recurrent or Refractory Acute Myeloid Leukemia and IDH2 Gene Mutation | NCT03683433 | Acute Bilineal ... Acute Biphenoty... Chronic Myelomo... IDH2 Gene Mutat... Myelodysplastic... Recurrent Acute... Refractory Acut... | Azacitidine Enasidenib Mesy... | 18 Years - | M.D. Anderson Cancer Center | |
| Personalized Targeted Preparative Regimen Before T-depleted Allogeneic HSCT in Children With Chemoresistent Acute Leukemias | NCT04000698 | Refractory Acut... Refractory Acut... | Preparative reg... | - 25 Years | Federal Research Institute of Pediatric Hematology, Oncology and Immunology | |
| Decitabine, Venetoclax, and Ponatinib for the Treatment of Philadelphia Chromosome-Positive Acute Myeloid Leukemia or Myeloid Blast Phase or Accelerated Phase Chronic Myelogenous Leukemia | NCT04188405 | Accelerated Pha... Acute Myeloid L... Blast Phase Chr... Recurrent Acute... Recurrent Chron... Refractory Acut... Refractory Chro... | Decitabine Ponatinib Venetoclax | 18 Years - | M.D. Anderson Cancer Center | |
| Entrectinib in Combination With ASTX727 for the Treatment of Relapsed/Refractory TP53 Mutated Acute Myeloid Leukemia | NCT05396859 | Acute Myeloid L... Recurrent Acute... Refractory Acut... | Decitabine and ... Entrectinib Laboratory Biom... | 18 Years - | OHSU Knight Cancer Institute | |
| Palbociclib and Sorafenib, Decitabine, or Dexamethasone in Treating Patients With Recurrent or Refractory Leukemia | NCT03132454 | Recurrent Acute... Recurrent Acute... Refractory Acut... Refractory Acut... | Decitabine Dexamethasone Palbociclib Sorafenib | 15 Years - | M.D. Anderson Cancer Center | |
| CPX-351 and Ivosidenib for the Treatment of IDH1 Mutated Acute Myeloid Leukemia or High-Risk Myelodysplastic Syndrome | NCT04493164 | Acute Myeloid L... Myelodysplastic... Myeloproliferat... Recurrent Acute... Refractory Acut... | Ivosidenib Liposome-encaps... | 18 Years - | M.D. Anderson Cancer Center | |
| Nivolumab and Azacitidine With or Without Ipilimumab in Treating Patients With Refractory/Relapsed or Newly Diagnosed Acute Myeloid Leukemia | NCT02397720 | Acute Bilineal ... Acute Biphenoty... Acute Myeloid L... Chronic Myelomo... Myelodysplastic... Recurrent Acute... Refractory Acut... Secondary Acute... Therapy-Related... | Azacitidine Ipilimumab Laboratory Biom... Nivolumab | 18 Years - | M.D. Anderson Cancer Center | |
| Ixazomib, Mitoxantrone Hydrochloride, Etoposide, and Intermediate-Dose Cytarabine in Relapsed or Refractory Acute Myeloid Leukemia | NCT02070458 | Recurrent Adult... Refractory Acut... | ixazomib mitoxantrone hy... etoposide cytarabine | 18 Years - 70 Years | Case Comprehensive Cancer Center | |
| Decitabine/Cedazuridine and Venetoclax in Combination With Ivosidenib or Enasidenib for the Treatment of Relapsed or Refractory Acute Myeloid Leukemia | NCT04774393 | Acute Myeloid L... Recurrent Acute... Refractory Acut... | Decitabine and ... Enasidenib Ivosidenib Venetoclax | 18 Years - | M.D. Anderson Cancer Center | |
| A Study of ASP2215 Versus Salvage Chemotherapy in Patients With Relapsed or Refractory Acute Myeloid Leukemia (AML) With FMS-like Tyrosine Kinase (FLT3) Mutation | NCT02421939 | Leukemia, Acute... | gilteritinib LoDAC (Low Dose... Azacitidine MEC (Mitoxantro... FLAG-IDA (Granu... | 18 Years - | Astellas Pharma Inc | |
| Pembrolizumab and Decitabine With or Without Venetoclax in Treating Patients With Acute Myeloid Leukemia or Myelodysplastic Syndrome That Is Newly-Diagnosed, Recurrent, or Refractory | NCT03969446 | Acute Myeloid L... Myelodysplastic... Recurrent Acute... Recurrent Myelo... Refractory Acut... Refractory Myel... | Decitabine Pembrolizumab Venetoclax | 18 Years - | City of Hope Medical Center | |
| BXCL701 Phase 1 R/R Acute Myeloid Leukemia or Myelodysplastic Syndrome | NCT05703542 | Acute Myeloid L... Myelodysplastic... | BXCL701 | 18 Years - | Dana-Farber Cancer Institute | |
| Palbociclib and Sorafenib, Decitabine, or Dexamethasone in Treating Patients With Recurrent or Refractory Leukemia | NCT03132454 | Recurrent Acute... Recurrent Acute... Refractory Acut... Refractory Acut... | Decitabine Dexamethasone Palbociclib Sorafenib | 15 Years - | M.D. Anderson Cancer Center | |
| Liposomal Cytarabine and Daunorubicin (CPX-351) and Quizartinib for the Treatment of Acute Myeloid Leukemia and High Risk Myelodysplastic Syndrome | NCT04128748 | Acute Myeloid L... Blasts More Tha... High Risk Myelo... Recurrent Acute... Recurrent Myelo... Refractory Acut... Refractory Myel... | Liposome-encaps... Quizartinib | 18 Years - | M.D. Anderson Cancer Center |
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
